[1] 陈琪,陆建,郭金和.晚期非小细胞肺癌免疫治疗研究进展[J].东南大学学报(医学版),2021,40(4):536-541.
[2] ZHANG J T,DONG S,JI L Y,et al.Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0(diameter ≥7 cm) non-small cell lung cancers[J].Thoracic cancer,2022,13(9):1333-1341.
[3] FOIJER F,ALBACKER L A,BAKKER B,et al.Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma[J].eLife,2017,6:e20873.
[4] TAKEI N,TAKADA Y,KAWAMURA S,et al.Changes in subcellular structures and states of pumilio 1 regulate the translation of target Mad2 and cyclin B1 mRNAs[J].J Cell Sci,2020,133(23):jcs249128.
[5] LI Y,BENEZRA R.Identification of a human mitotic checkpoint gene:hsMAD2[J].Science,1996,274(5285):246-248.
[6] UZBEKOV R,PRIGENT C.A journey through time on the discovery of cell cycle regulation[J].Cells,2022,11(4):704.
[7] 罗政,路名芝,刘勇.大肠癌细胞周期G1/S期检查点调控的研究进展[J].中国肿瘤,2003(4):37-39.
[8] 高燕,林莉萍,丁健.细胞周期调控的研究进展[J].生命科学,2005(4):318-322.
[9] WANG Y,WANG F,HE J,et al.MiR-30a-3p targets MAD2L1 and regulates proliferation of gastric cancer cells[J].Onco Targets Ther,2019,12:11313-11324.
[10] PACK L R,DAIGH L H,MEYER T.Putting the brakes on the cell cycle:mechanisms of cellular growth arrest[J].Curr Opin Cell Biol,2019,60:106-113.
[11] SHERR C J,ROBERTS J M.Living with or without cyclins and cyclin-dependent kinases.[J].Genes Dev,2004,18(22):2699-2711.
[12] LABIB K,DE PICCOLI G.Surviving chromosome replication:the many roles of the S-phase checkpoint pathway[J].Philos Trans R Soc Lond B Biol Sci,2011,366(1584):3554-3561.
[13] BLACKFORD A N,JACKSON S P.ATM,ATR,and DNA-PK:the trinity at the heart of the DNA damage response[J].Mol Cell,2017,66(6):801-817.
[14] SCHVARTZMAN J,DUIJF P H G,SOTILLO R,et al.Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition[J].Cancer cell,2011,19(6):701-714.
[15] JUNG Y,KRAIKIVSKI P,SHAFIEKHANI S,et al.Crosstalk between Plk1,P53,cell cycle,and G2/M DNA damage checkpoint regulation in cancer:computational modeling and analysis[J].NPJ Syst Biol Appl,2021,7(1):46.
[16] HARDWICK K G,LI R,MISTROT C,et al.Lesions in many different spindle components activate the spindle checkpoint in the budding yeast Saccharomyces cerevisiae[J].Genetics,1999,152(2):509-518.
[17] SKOUFIAS D A,ANDREASSEN P R,LACROIX F B,et al.Mammalian mad2 and bub1/bubR1 recognize distinct spindle-attachment and kinetochore-tension checkpoints[J].Proc Natl Acad Sci U S A,2001,98(8):4492-4497.
[18] WATERS J C,CHEN R H,MURRAY A W,et al.Localization of Mad2 to kinetochores depends on microtubule attachment,not tension[J].J Cell Biol,1998,141(5):1181-1191.
[19] HAJERI V A,STEWART A M,MOORE L L,et al.Genetic analysis of the spindle checkpoint genes san-1,mdf-2,bub-3 and the CENP-F homologues hcp-1 and hcp-2 in Caenorhabditis elegans[J].Cell Div,2008,3:6.
[20] SUDAKIN V,CHAN G K,YEN T J.Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1,BUB3,CDC20,and MAD2[J].J Cell Biol,2001,154(5):925-936.
[21] PINES J.Cubism and the cell cycle:the many faces of the APC/C.[J].Nat Rev Mol Cell Biol,2011,12:427-438.
[22] SINHA D,DUIJF P H G,KHANNA K K.Mitotic slippage:an old tale with a new twist[J].Cell cycle,2019,18(1):7-15.
[23] HENNINGSEN K M,MANZINI V,MAGERHANS A,et al.MDM2-driven ubiquitination rapidly removes p53 from its cognate promoters[J].Biomolecules,2021,12(1)：22.
[24] YU H.Structural activation of Mad2 in the mitotic spindle checkpoint:the two-state Mad2 model versus the Mad2 template model[J].J Cell Biol,2006,173(2):153-157.
[25] JOHNSTON S R D,HARBECK N,HEGG R,et al.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+,HER2-,Node-Positive,High-Risk,early breast cancer(monarchE)[J].J Clin Oncol,2020,38(34):3987-3998.
[26] PIEZZO M,COCCO S,CAPUTO R,et al.Targeting cell cycle in breast cancer:CDK4/6 inhibitors[J].Int J Mol Sci,2020,21(18):6479.
[27] YANG W,PAN Y,YOU C.CDK1,CCNB1,CDC20,BUB1,MAD2L1,MCM3,BUB1B,MCM2,and RFC4 may be potential therapeutic targets for hepatocellular carcinoma using integrated bioinformatic analysis[J].Biomed Res Int,2019,2019:1245072.
[28] DING X,DUAN H,LUO H.Identification of core gene expression signature and key pathways in colorectal cancer[J].Front Genet,2020,11:45.
[29] LU S,SUN C,CHEN H,et al.Bioinformatics analysis and validation identify cdk1 and mad2l1 as prognostic markers of rhabdomyosarcoma[J].Cancer Manag Res,2020,12:12123-12136.
[30] WU X,PENG L,ZHANG Y,et al.Identification of key genes and pathways in cervical cancer by bioinformatics analysis[J].Int J Med Sci,2019,16(6):800-812.
[31] LU X,ZHANG J,ZHANG S,et al.Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis[J].BMC Cancer,2021,21(1):697.
[32] SU L,ZHANG J,ZHANG X,et al.Identification of cell cycle as the critical pathway modulated by exosome-derived microRNAs in gallbladder carcinoma[J].Med Oncol,2021,38(12):141.
[33] SHI Y,ZHU T,ZOU T,et al.Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma[J].Oncotarget,2016,7(51):85235-85243.
[34] 王丽,刘成凤,魏丽群,等.非小细胞肺癌患者外周血PD-L1蛋白的表达及其对治疗效果的评估作用[J].贵州医科大学学报,2021,46(5):584-589.
[35] 周利君,郭红荣,王红娟,等.非小细胞肺癌组织中LINC00707、miR-382-5p表达及其与患者预后的关系[J].东南大学学报(医学版),2023,42(5):724-729.
[36] 王蓓,宋子正.非小细胞肺癌免疫相关生物标志物的研究进展[J].实用药物与临床,2023,26(3):269-275.
[37] HANEKE K,SCHOTT J,LINDNER D,et al.CDK1 couples proliferation with protein synthesis[J].J Cell Biol,2020,219(3):e201906147.
[38] 马玉博,潘博,赵若晗,等.肺腺癌中CDK1的生物信息学分析[J].包头医学院学报,2022,38(7):33-38.
[39] 游路宽,郑轩,胡毅.肺鳞癌潜在关键基因的生物信息学分析[J].解放军医学院学报,2018,39(10):903-909.
[40] 黄河,李成长,彭燕,等.肺腺癌关键基因的鉴别及预后[J].中国老年学杂志,2022,42(1):33-37.
[41] GUO Y,ZHANG X,YANG M,et al.Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer[J].J Med Genet,2010,47(9):616-622.
[42] 阿丽亚·奥斯曼,王效刚,刘俊远,等.小细胞肺癌内科治疗新进展[J].现代肿瘤医学,2023,31(7):1362-1366.
[43] RUDIN C M,BRAMBILLA E,FAIVRE-FINN C,et al.Small-cell lung cancer[J].Nat Rev Dis Primers,2021,7(1):3.
[44] RUDIN C M,DURINCK S,STAWISKI E W,et al.Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer[J].Nat Genet,2012,44(10):1111-1116.
[45] NI Z,WANG X,ZHANG T,et al.Comprehensive analysis of differential expression profiles reveals potential biomarkers associated with the cell cycle and regulated by p53 in human small cell lung cancer.[J].Exp Ther Med,2018,15(4):3273-3282.
[46] LIAO Y,YIN G,WANG X,et al.Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis[J].Oncol Lett,2019,18(4):3723-3733.
[47] CHEN X,WANG L,SU X,et al.Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples[J].PLoS One,2020,15(11):e242194.
[48] LARA-GONZALEZ P,WESTHORPE F G,TAYLOR S S.The spindle assembly checkpoint[J].Curr Biol,2012,22(22):R966-R980.
[49] WU Y,TAN L,CHEN J,et al.MAD2 combined with mitotic spindle apparatus(MSA) and anticentromere antibody(ACA) for diagnosis of small cell lung cancer(SCLC)[J].Med Sci Monit,2018,24:7541-7547.
[50] LI Y,FAN H,DING J,et al.Microfluidic devices:the application in TME modeling and the potential in immunotherapy optimization[J].Front Genet,2022,13:969723.
[51] BAKHOUM S F,CANTLEY L C.The Multifaceted role of chromosomal instability in cancer and its microenvironment[J].Cell,2018,174(6):1347-1360.
[52] CHEN S,YANG M,YANG H,et al.Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis[J].Ann Transl Med,2022,10(19):1059.
[53] ZHANG S,PANG K,FENG X,et al.Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma[J].Sci Rep,2022,12(1):13214.
[54] ALIKHANYAN K,CHEN Y,SOMOGYI K,et al.Mad2 induced aneuploidy contributes to Eml4-Alk driven lung cancer by generating an immunosuppressive environment[J].Cancers(Basel),2021,13(23).
[55] DAVOLI T,UNO H,WOOTEN E C,et al.Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy[J].Science,2017,355(6322):eaaf8399.
[56] 刘迎博,刘晓红,茹美华,等.MAD2L1在肺腺癌中的表达及对免疫微环境的影响[J].肿瘤防治研究,2022,49(6):586-592. |
